NPPA and depressive symptom measurement: With the determination of immunomodulatory property of sCD83 and related mechanisms, an expanded neuroimmunomodulation axis, sCD83-IDO-KP, was formed, which had been proved to have important impacts on the development of various neurological diseases, including ischemic stroke, epilepsy, AD, multiple sclerosis, PD, and depression.